Challenge and opportunity of targeted lung cancer chemoprevention.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.Oncotarget · 2017
   Article
2. ATM/CHK/p53 Pathway Dependent Chemopreventive and Therapeutic Activity on Lung Cancer by Pterostilbene.PloS one · 2016
   Article
3. Enhanced antitumor activity of 3-bromopyruvate in combination with rapamycin in vivo and in vitro.Cancer prevention research (Philadelphia, Pa.) · 2015
   Article
4. Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy.Cancer prevention research (Philadelphia, Pa.) · 2014
   Article

Corrections and comments

• Comment on
  Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.2013

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as